Special report on the 2007 adult and pediatric Position Development Conferences of the International Society for Clinical Densitometry
- 336 Downloads
The International Society for Clinical Densitometry (ISCD) conducts Position Development Conferences (PDCs) for the purpose of establishing standards and guidelines in the field of bone densitometry. Topics for consideration are selected according to clinical relevance, a perceived need for standardization, and the likelihood of achieving agreement. Questions regarding nomenclature, indications, acquisition, analysis, quality control, interpretation, and reporting of bone density tests for each topic area are assigned to task forces for a comprehensive review of the scientific literature. The findings of the review and recommendations are then presented to an international panel of experts at the PDC. The expert panel votes on potential Official Positions for appropriateness, necessity, quality of the evidence, strength of the recommendation, and applicability (worldwide or variable according to local requirements). Recommendations that are approved by the ISCD Board of Directors become Official Positions. The first Pediatric PDC was 20–21 June 2007 in Montreal, QC, Canada. The most recent Adult PDC was held 20–22 July 2007, in Lansdowne, VA, USA. This Special Report summarizes the methodology of the ISCD PDCs and presents selected Official Positions of general interest.
KeywordsBMD testing DXA Guidelines ISCD Official positions Osteoporosis Recommendations Standards
Conflicts of interest
S. Baim: none.
N. Binkley: consultant for Merck, Novartis, Lilly; research funding from Merck, Novartis, Roche, Aventis, GSK, Deltanoid; speaker for Merck, Roche, P&G, GSK.
D.B. Hans: ownership interest in Synarc, Inc.; research funding from Servier.
D.L. Kendler: consultant for Merck, Pfizer, Servier, Lilly, Novartis, Amgen; educational grants from Merck, Pfizer, Servier, Lilly, Novartis, Amgen, P&G; honoraria from Merck, Pfizer, Servier, Lilly, Novartis, Amgen, P&G; research funding from Merck, Pfizer, Servier, Lilly, Novartis, Amgen, P&H, Takeda, Wyeth, Zelos, J&J; speaker for Merck, Servier, Lilly, Novartis, Amgen, P&G.
E.M. Lewiecki: committee chair for ISCD; educational grants from P&G, Amgen, Novartis; honoraria from Merck, Lilly, P&G, Roche, GSK, Novartis; officer or board member for ISCD; ownership interest in GE Healthcare, P&G; research funding from Merck, P&G, Roche, Lilly, Amgen, Novartis; speaker for Merck, Lilly, P&G, Roche, GSK, Novartis.
J.P. Bilezikian: consultant for P&G, sanofi-aventis, Merck, Amgen, Lilly; officer or board member for P&G, sanofi-aventis, Merck, Amgen, Lilly.
S.L. Silverman: consultant for Merck, P&G, Wyeth, Roche, Novartis; officer or board member for Compumed; research funding from Novartis, Lilly, Wyeth, Roche, P&G, Merck; speaker for Lilly, Merck, P&G, Roche.
M.B. Leonard: None.
M.-L. Bianchi: educational grants from Telethon; VILDM research funding from Telethon.
H. Kalkwarf: employee of P&G; stock in P&G.
F. Rauch: none.
C.B. Langman: director of institutional research for Amgen: research funding from Amgen.
H. Plotkin: none.
N.J. Bishop: consultant for P&G; research funding from Alliance for Better Bone Health, Novartis.
C.M. Gordon: none.
B.S. Zemel: consultant for Johnson & Johnson; research funding from Quest Diagnostics, Nichols Research Institute.
- 6.Cochrane (2002) Cochrane Reviewer’s Handbook, 4.1.5. Available from www.cochrane.org/software/Documentation/Handbook/ handbook.pdf.
- 7.Fitch K, Bernstein SJ, Aguilar B et al (2001) The RAND/UCLA Appropriateness Method User’s Manual. RAND, Santa MonicaGoogle Scholar